Isolate Data
| Patient | Isolate | Region | Year | Species | Subtype | Source | Clone Method |
| CA4068 | CA9692 | U.S. | 1999 | HIV1 | B | Plasma | None |
Treatment History
| Order | Regimen | Weeks |
| 1 | AZT | 43 |
| 2 | AZT+DDC | 55 |
| 3 | DDI | 6 |
| 4 | D4T | 37 |
| 5 | 3TC+D4T | 25 |
| 6 | 3TC+AZT | 5 |
| 7 | 3TC+AZT+SQV | 28 |
| 8 | 3TC+AZT+IDV | 8 |
| 9 | 3TC+D4T+IDV | 23 |
| 10 | 3TC+D4T+RTV+SQV | 2 |
| 11 | 3TC+D4T+IDV | 9 |
| 12 | 3TC+D4T+NFV | 5 |
| 13 | 3TC+IDV+NVP | 47 |
| 14 | 3TC+NVP+RTV+SQV | 39 |
| 15 | 3TC+RTV+D4T+SQV | 1 |
Protease Sequence
| PIMajorDRMs | PIMinorDRMs | Polys | UnusualMuts |
| M46L, L90M | F53L, G73S | L10V, N37T, K55R, L63P, C67F, A71V, V77I, C95L |
| >CA9692| codons 1-99 PQITLWQRPVVTIKIGGQLKEALLDTGADDTVLEEMTLPGRWKPKLIGGIGGLIRVRQYD QIPIEIFGHKVISTVLIGPTPVNIIGRNLMTQIGLTLNF |
RT Sequence
| NRTIMajorDRMs | NRTIMinorDRMs | NNRTIMajorDRMs | NNRTIMinorDRMs | Polys | UnusualMuts |
| M41L, D67N, K70R, L74V, V75M, M184V, L210W, T215Y | K219Q | K103T, M230L | K238T | T39A, V60I, L109M, V118I, K122E, I142V, E203K, Q207E, H208Y, R211K, D218E, L228H, K277R, T286A | L187M |
| >CA9336| codons 1-303 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALVEICAELEKEGKISKIGPENPYNTPI FAIKKKNSTRWRKVMDFRELNKRTQDFWEVQLGIPHPAGLKKTKSVTVMDVGDAYFSIPL DEDFRKYTAFTIPSINNETPGVRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPDIVI YQYVDDMYVGSDLEIGQHRTKIKELREYLWKWGFYTPEQKHQKEPPFHWLGYELHPDTWT VQPIVLPEKDSWTVNDIQKLVGKLNWASQIYAGIKVRQLCKLLRGAKALTEVIPLTEEAE LEL |
References
| Author | Title | Citation |
| Gonzales, MJ | HIV-1 reverse transcriptase and protease subtypes: classification, amino acid mutation patterns, and prevalence in a Northern California clinic-based population. | J Infect Dis, 2001 |
| Gonzales, MJ | Protease and reverse transcriptase mutation patterns in HIV-1 isolates from heavily treated persons: comparison of isolates from northern California with isolates from other regions. | ARHR, 2003 |
| Rhee, SY | HIV-1 Protease and Reverse Transcriptase Mutations: Correlations with Antiretroviral Therapy in Subtype B Isolates and Implications for Drug-Resistance Surveillance. | J Infect Dis, 2005 |